Innoviva (INVA) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.66% |
| Dec 31, 2025 | -17.68% |
| Sep 30, 2025 | 26.08% |
| Jun 30, 2025 | -3.69% |
| Mar 31, 2025 | -22.08% |
| Dec 31, 2024 | -17.39% |
| Sep 30, 2024 | -50.25% |
| Jun 30, 2024 | -23.89% |
| Mar 31, 2024 | 1.57% |
| Dec 31, 2023 | -15.15% |
| Sep 30, 2023 | 11.74% |
| Jun 30, 2023 | -52.80% |
| Mar 31, 2023 | 3.34% |
| Dec 31, 2022 | -16.83% |
| Sep 30, 2022 | 62.04% |
| Jun 30, 2022 | -51.54% |
| Mar 31, 2022 | -1.31% |
| Dec 31, 2021 | -17.44% |
| Sep 30, 2021 | 36.96% |
| Jun 30, 2021 | 43.54% |
| Mar 31, 2021 | 84.23% |
| Dec 31, 2020 | 65.81% |
| Sep 30, 2020 | 52.16% |
| Jun 30, 2020 | 63.93% |
| Mar 31, 2020 | 52.08% |
| Dec 31, 2019 | 37.33% |
| Sep 30, 2019 | 31.09% |
| Jun 30, 2019 | 21.00% |
| Mar 31, 2019 | 20.10% |
| Dec 31, 2018 | 48.75% |
| Sep 30, 2018 | 24.59% |
| Jun 30, 2018 | 28.47% |
| Mar 31, 2018 | 22.79% |
| Dec 31, 2017 | 31.04% |
| Sep 30, 2017 | 21.84% |
| Jun 30, 2017 | 24.13% |
| Mar 31, 2017 | -27.59% |
| Dec 31, 2016 | 21.97% |
| Sep 30, 2016 | 20.02% |
| Jun 30, 2016 | 20.90% |
| Mar 31, 2016 | 17.03% |
| Dec 31, 2015 | 17.32% |
| Sep 30, 2015 | 26.40% |
| Jun 30, 2015 | 17.80% |